Bimatoprost/timolol ocular insert - Allergan

Drug Profile

Bimatoprost/timolol ocular insert - Allergan

Alternative Names: Bimatoprost/timolol HELIOS™ insert - Allergan; Timolol/bimatoprost ocular insert - Allergan

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ForSight VISION5
  • Developer Allergan
  • Class Amides; Antiglaucomas; Antihypertensives; Lipids; Morpholines; Propanolamines; Synthetic prostaglandins; Thiadiazoles
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Dec 2016 ForSight Vision5 completes a phase I/II trial in Ocular hypertension and Glaucoma in Panama (Ophthalmic) (NCT02742649)
  • 01 Mar 2016 Phase-I/II clinical trials in Glaucoma in Panama (Ophthalmic) (NCT02742649)
  • 01 Mar 2016 Phase-I/II clinical trials in Ocular hypertension in Panama (Ophthalmic) (NCT02742649)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top